Study S001300

Effect of Semaglutide in Patients With Psoriasis and Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06937060
Acronym: SEMPSO
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: RECRUITING
Enrollment: 14
Start: 2025-03-20
Primary completion: 2026-07-31
Lead sponsor: The University of Hong Kong
Conditions: Psoriasis (PsO); Obesity and Overweight
Interventions: BIOLOGICAL:semaglutide
Results posted: FALSE

Registered primary outcomes

Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment. [36 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.